In 2012, Mun et al.reported a novel HIF-1 pathway inhibitor withimproved pharmacological properties as a potential anti-glioma agent.85 The group used compound 130, whichwas previously identified through high-throughput screening as a lead.The lead modification study was initiated to overcome the limitationof the poor aqueous solubility of 130 that was pinpointedas an obstacle for the in vivo evaluations. Here, HIF1A is linked to glioma.